US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Forthcoming changes in Inhalation Sciences’ Board of Directors

Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Nomination Committee proposes that Ulf Ericsson be elected as new Board member.The Company intends to convene an Extraordinary General Meeting where the Nomination Committee proposes that Ulf Ericsson be elected as a new Board member. “The Inhalation Science’s Board is very excited about the nomination of Ulf as a new Board member in the company. Given Ulf’s long experience and deep understanding of the inhalation research market as well as good insights into the needs and requirements of our customers, he

Watch ISAB CEO go behind the headlines in high-value Q1 interview

Inhalation Sciences CEO Manoush Masarrat discusses the company’s recent Q1 Report, and takes investors’ questions, in the first of a new regular series.Watch the interview here . Together with analyst Jonathan Furelid ISAB’s CEO analyzes the Company’s recent Q1 results, taking investor’s questions and adding significant business intelligence and insights. The interview is the first in a series of Quarterly videos that will run through 2024.

Inhalation Sciences AB (publ) releases Q1 Report 2024

(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement Our first quarter started out strong with an increased revenue of 17% compared to the same period the year before. We also have a continued improved operating profit through continuous cost control and a streamlined organization that is designed to reach profitability in the near term and deliver growth according to our plan. Through

Inhalation Sciences presents at well-received FDA public workshop GDUFA

On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s public GDUFA (Generic Drug User Fee Amendments) webinar (as previously communicated on April 10, 2024). The webinar was well-attended and well-received by a large audience of specialist industry professionals.ISAB’s webinar session at the workshop was titled “Predictive Tools for Generic Product Development & Assessment”. It was held by ISAB CSO and Founder Per Gerde and ISAB’s Director of Projects Dr Maria Malmlöf. Engagement

Inhalation Sciences receives new order worth 60,000 Euro from long-term big pharma client

Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.The order is for essential spare parts and consumables for the client’s PreciseInhale® system. The client is a long-term customer of ISAB’s with a world-class generics pipeline and robust R&D organisation. Prior to its purchase and installation of PreciseInhale® the client carried

Inhalation Sciences AB (publ) releases Annual Report 2023

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO comments 2023 was another year in which we continued to take new market share and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 44% from 2022 to 2023. At the same time, we have also significantly improved our operating profit during the same period. With this positive development, we

Inhalation Sciences to present at FDA’s public workshop GDUFA on May 20th, 2024

Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20[th], 2024.The annual GDUFA Public Workshop is open and free to the public, and any member of the public may provide comments to the docket for the meeting or may provide their public comments in a prepared presentation, or as impromptu comments. The FDA routinely announces the workshop and provides information about how the public may provide comments. This includes information about how the public can submit a

Positive results of first-in-human clinical trial of PreciseInhale now published in European Journal of Pharmaceutical Sciences

(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system PreciseInhale® are now published in a peer-reviewed paper in the European Journal of Pharmaceutical Sciences. The results demonstrate that PreciseInhale® provides greater precision and control than aerosol dosing carried out with a standard commercial inhaler, and can be used for ‘regional targeting’, exposing specific regions of the lungs to a targeted aerosol. The topline results were first communicated on December 20, 2021.The paper is titled Regional lung

Inhalation Sciences signs new partnership with Actarmo Medical: End-to-end offering for respiratory drug development Services

Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH based in Germany. The new partnership is expected to enlarge the service scope and offerings to the client pipelines of both companies. ISAB and Actarmo have highly complementary services at either end of the respiratory drug development chain, in the fast-growing inhaled therapeutics market.Inhalation Sciences AB has entered a new partnership with Actarmo Medical GmbH, a respiratory drug development services provider headquartered in Gauting, Germany.

Inhalation Sciences’ captures interest and interaction at its latest industry webinar ‘Inhaled Biologics’

(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics’. Over 200 scientists registered for the event, the latest in ISAB’s highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.On December 11 at 11AM EST ISAB held the latest in its popular series of co-hosted industry webinars. The series has become a regular fixture for many scientists working in inhaled therapeutics and drug development,

Inhalation Sciences wins new purchase order worth 276,450 Euro (3.2 MSEK)

(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB’s aerosol generating platform PreciseInhale and its unique cell exposure module.The returning client is a loyal customer and has long been a keen advocate of ISAB’s unique multi-modular, precision dosing aerosol system PreciseInhale. Within inhalation the customer has an extensive, competitive portfolio and robust pipeline. PreciseInhale –

Inhalation Sciences secures new order worth 54,700 Euro

(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.Inhalation Sciences has received an order valued at 54,700 Euro with a new customer in Europe developing a generic inhaled drug-device combination therapy. The project will carry out required regulatory testing through a trusted service partner, sourced by ISAB, that

Inhalation Sciences’ CEO at Redeye Life Science Day 2023

Join Inhalation Sciences AB (ISAB) CEO Manoush Masarrat for a 2-minute company pitch and 20-minute analyst Q&A at the livestreamed Redeye Life Science Day, November 23, 2023.ISAB has achieved robust growth for sales of its unique, high-precision platform technology and Inhalation Research Services (IRS), with a Q2 revenue increase of 36% compared to the same period last year, and a 500% growth in signed sales orders compared to the same period in the preceding year. Manoush will be joining a host of other Nordic Life Science executives at the event. Don't miss the opportunity to learn

Inhalation Sciences secures 188,900 Euro order from top-five global generics manufacturer

Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project. The client has once again chosen DissolvIt, ISAB’s in vitro dissolution testing module, known for its precise prediction and comparison of how test generic formulations and originator products perform in the lung. DissolvIt provides a unique advantage for developers of complex generic inhaled therapies. DissolvIt testing is being adopted by a growing number of generic and novel biopharma companies.The returning client is amongst the world’s top five generic

Inhalation Sciences signs collaboration agreement with leading Indian multinational pharma company

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.The company is ISAB’s first Indian client and is a highly agile, innovative multinational with a large number of development projects ongoing and a YoY R&D investment that has grown continuously over recent years. The Indian pharmaceutical industry as a whole is a

Inhalation Sciences AB (publ) releases Q2 Report 2023

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q2 Report for 2023 is now available on the company’s website.To read the whole report (in Swedish) visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement During the second quarter, we have continued to deliver on our strategic goals with a focus on commercial activities, where revenue has increased by 36% compared to the same period last year. Sales in the form of new signed orders have also continued in the right direction with an increase of over 500% compared to the same period last

Inhalation Sciences AB (publ) to repay its loan by end of August 2023

(Stockholm, Sweden, 23 August 2023) Inhalation Sciences AB will repay a 1.8 MSEK loan which was reported in the Q1 Report 2023. The loan will be repaid by the end of August 2023. The contractual due date for repayment is December 2023. The total amount including interest and setup fee is approx. 2.6 MSEK.In the Q1 Report (31 May 2023) ISAB reported that on January 16[th], 2023 it had activated 1.8 MSEK of its credit facility, due to be repaid in December 2023. ISAB will now in advance repay the loan by the end of August 2023. The total loan amount is approx. 2.6 MSEK, including interest and

Inhalation Sciences receives Purchase Order worth 125.8 KEURO from international distributor for Asia

Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.8 KEuro (1.47 MSEK), from an international distributor for Asia. The new order is for PreciseInhale, ISAB’s unique aerosol generation system, with additional modules.PreciseInhale is unique within inhaled drug development as a ‘precision dosing’ system. Unlike standard ‘tower testing’ systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development. ISAB has recently increased the focus of its

Inhalation Research Services wins new order worth 98,000 Euro from returning US customer

Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first in vitro technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.The returning client is a midsize US pharma company developing inhaled therapies.

Inhalation Sciences AB (publ) releases Q1 Report 2023

(Stockholm, Sweden, 31 May 2023) Inhalation Sciences AB announces that its Q1 Report for 2023 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/CEO statement We started the year with a strong order backlog that was the result of a successful closing of sales in 2022. Operationally, our focus has been on meeting the increased order intake and delivering projects to our customers of the highest quality. Revenues in the first quarter increased by 57% compared to the same period last year and

Inhalation Sciences receives 125,000 EURO funding in cross-European research project on inhaled antibiotics and antibiotic resistance

(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project ‘New Inhalation Formulations for Improved Delivery of Antimicrobials’ (APRINHA). ISAB is one of seven organizations collaborating on this project, including RISE (the Research Institutes of Sweden.) ISAB announced that it had collaborated with RISE on a joint funding proposal for the project on June 9, 2022. The project will run for 36 months. It is being coordinated by the University of Zurich (UZH).The unmet need for a targeted, efficacious inhaled antibiotic treatment

Inhalation Sciences receives new order worth 53,000 Euro from returning customer

Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhaled therapies with a strong development pipeline based in Europe. The order is for additional modules and accessories that will expand the client’s two existing PreciseInhale systems.The client is a loyal ISAB customer, with two PreciseInhale systems in place. The client’s team carry out advanced in vivo work on New Chemical Entities, using the highly accurate preclinical data generated by PreciseInhale to significantly reduce risk in the later clinical

Inhalation Sciences receives green light from the US FDA to start the experimental phase of FDA BAA dissolution research project

(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project, ISAB today announces that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company’s facilities in Sweden.The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB’s DissolvIt technology by comparing drug formulations, aimed for administration via inhalation, with

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe